Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF

Plasma long pentraxin 3 as a marker of endothelial dysfunction in early diabetic nephropathy

The Egyptian Journal of Internal Medicine volume 25, pages 117–126 (2013)Cite this article

Abstract

Objective

This study investigated the utility of measuring plasma long pentraxin 3 (PTX3) levels in the early detection of endothelial dysfunction compared with Von Willebrand factor (vWF) activity and flow-dependent arterial dilatation (well-known markers of endothelial dysfunction) in early diabetic nephropathy.

Materials and methods

A total of 50 Egyptian patients with type 2 diabetes and 20 healthy controls were recruited from the Diabetes, Endocrinology and Metabolism center, Faculty of Medicine, Cairo University. The diabetic patients were divided into two equal groups of comparable age and sex: group I consisted of patients with normal urinary albumin excretion and group II consisted of patients with microalbuminuria.

Results

In group II, the plasma PTX3 level was significantly higher (median value 2.3 ng/ml) and the mean flow-mediated dilatation (FMD; 0.433 ±0.059) was significantly lower when compared with the control group (PTX3 1.15 ng/ml, FMD 0.901 ± 0.04; P<00001) and with group I (PTX3 1.2 ng/ml, FMD 0.627± 0.05; P<0.0001). The vWF activity (median value) was significantly higher in the two diabetic groups compared with controls (20.2, 16.3 and 4% in group I, group II, and controls, respectively; P<0.0001), with no significant difference between the two diabetic groups. There was a significant positive correlation between PTX3 levels and vWF activity (P<0.001), diabetes duration, and concentration of fasting blood sugar, HbA1c, cholesterol, and triglyceride and a significant negative correlation between PTX3 levels and FMD (P<0.001) in all diabetic patients. In group II, there was a significant positive correlation between PTX3 levels and vWF activity (r= 0.603, P= 0.001).

Conclusion

PTX3 may represent a useful endothelial dysfunction marker in early diabetes nephropathy.

References

  1. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001; 22: 36–52.

    Article  CAS  Google Scholar 

  2. Vallance P, Calver A, Collier J. The vascular endothelium in diabetes and hypertension. J Hypertens Suppl 1992; 10: S25–S29.

    Article  CAS  Google Scholar 

  3. Watts GF, O Brien SF, Silvester W, Millar JA, Millar JA. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non insulin dependent diabetes: role of dyslipidemia. Clin Sci (Lond) 1996; 91: 567–573.

    Article  CAS  Google Scholar 

  4. Cipola MJ, Harker CT, Porter JM. Endothelial function and adrenergic reactivity in human type II diabetic resistance arteries. J Vasc Surg 1996; 23: 940–949.

    Article  Google Scholar 

  5. Huszka M, Kaplar M, Rejto L, Tornai I, Palatka K, Laszlo P, Udvardy M. The association of reduced endothelium derived relaxing factor – NO production with endothelial damage and increased in vivo platelet activation in patients with diabetes mellitus. Thromb Res 1997; 86: 173–180.

    Article  CAS  Google Scholar 

  6. Huvers FC, De Leeuw PW, Houben AJ, De Haan CH, Hamulyak K, Schouten H, et al. Endothelium dependent vasodilatation, plasma markers of endothelial function and adrenergic vasoconstrictor responses in type 1 diabetes under near normoglycemic conditions. Diabetes 1999; 48: 1300–1307.

    Article  CAS  Google Scholar 

  7. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium dependent vasodilation in patients with insulin dependent diabetes mellitus. Circulation 1993; 88: 2510–2516.

    Article  CAS  Google Scholar 

  8. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801–813.

    Article  CAS  Google Scholar 

  9. Border WA, Yamamoto T, Noble NA. Transforming growth factor b in diabetic nephropathy. Diabetes Metab Rev 1996; 12: 309–339.

    Article  CAS  Google Scholar 

  10. Yu PH. Deamination of methylamine and angiopathy; toxicity of formaldehyde, oxidative stress and relevance to protein glycoxidation in diabetes. J Neural Transm Suppl 1998; 52: 201–216.

    Article  CAS  Google Scholar 

  11. Cacoub P, Carayon A, Dorent R, Nataf P, Chemlal K, Maistre G, et al. Endothelin: the vasoconstrictor of the 1990s? Rev Med Interne 1993; 14: 229–232.

    Article  CAS  Google Scholar 

  12. Lip GY, Blann A. Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997; 34: 255–265.

    Article  CAS  Google Scholar 

  13. Sixma JJ, de Groot PG. Von Willebrand factor and the blood vessel wall. Mayo Clinic Proc 1991; 66: 628–633.

    Article  CAS  Google Scholar 

  14. Sernau T, Wilhelm C, Seyfert U, Gabath S, Henkels M, Amiral J, et al. Thrombomodulin is a marker of microvascular but not for macrovascular endothelial cell damage. Vasa 1995; 24: 347–353.

    CAS  PubMed  Google Scholar 

  15. Richardson M, Hadcock SJ, DeReske M, Cybulsky MI. Increased expression in vivo of VCAM-1 and E-selectin by the aortic endothelium of normolipemic and hyperlipemic diabetic rabbits. Arterioscler Thromb 1994; 14: 760–769.

    Article  CAS  Google Scholar 

  16. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990; 227: 273–278.

    Article  CAS  Google Scholar 

  17. Todoric J, Handisurya A, Knapp B, Tura A, Pacini G, Kautzky-Willer A. Relationship of pentraxin 3 with insulin sensitivity in gestational diabetes. Eur J Clin Invest 2013; 43: 341–349.

    Article  CAS  Google Scholar 

  18. Barbui T, Carobbio A, Guido Finazzi G, Vannucchi AM, Barosi G, Antonioli E, et al. Inflammation and thrombosis in essential thrombothycemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 2011; 96: 315–318.

    Article  CAS  Google Scholar 

  19. Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005; 130: 709–715.

    Article  CAS  Google Scholar 

  20. Rolph MS, Zimmer S, Botttazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin 3 in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002; 22: e10–e14.

    Article  Google Scholar 

  21. Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, Latini R. The long pentraxin 3 in vascular pathology. Vascul Pharmacol 2006; 45: 326–330.

    Article  CAS  Google Scholar 

  22. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Lipid Assessment Trial Italian Network (LATIN) Investigators, prognostic significance of the long pentraxin 3 inacute myocardial infarction. Circulation 2004; 110: 2349–2354.

    Article  CAS  Google Scholar 

  23. Witasp A, Rydén M, Carrero JJ, Qureshi AR, Nordfors L, Näslund E, et al. Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. PLoS One 2013; 8: e63493. doi: 10.1371/journal.

    Article  CAS  Google Scholar 

  24. Witte DR, Westerink J, deKoning EJ, van der Graaf Y, Grobbee DE, Bots ML. Is the association between flow mediated dilation and cardiovascular risk limited to the low risk populations? J Am Coll Cardiol 2005; 45: 1987–1993.

    Article  Google Scholar 

  25. Ghiadoni L, Versari D, Magagna A, Kardasz I, Plantinga Y, Giannarelli C, et al. Ramipril dose dependently increases nitric oxide availability in the radial artery of essential patients. J Hypertens 2007; 25: 361–366.

    Article  CAS  Google Scholar 

  26. Cockcroft DW, Gault MH. ‘Prediction of creatinine clearance from serum creatinine’. Nephron 1976; 16: 31–41.

    Article  CAS  Google Scholar 

  27. Bazari H. Approach to the patient with renal disease. In: Goldman L, Ausiello D, editors. Cecil medicine. 23rd ed Philadelphia, PA: Saunders Elsevier; 2007. pp. 708–715.

  28. Goodall AH. An immunoradiometric assay for human factor vIII/von Willebrand factor using a monoclonal antibody that defines a functional epitope. Br J Haematol 1985; 59: 565–577.

    Article  CAS  Google Scholar 

  29. Bottazzi B, Vouret-Craviari V, Bastone A. Multimer formation and ligand recognition by the long pentraxin 3. J Biol Chem 1997; 272: 32817–32823.

    Article  CAS  Google Scholar 

  30. Alam TA, Seifalian AM, Baker D. A review of methods currently used for assessment of in vivo endothelial function. Eur J Vasc Endovasc Surg 2005; 29: 269–276.

    Article  CAS  Google Scholar 

  31. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc 2011; 86: 444–456.

    Article  CAS  Google Scholar 

  32. Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci 2013; 124: 139–152.

    Article  CAS  Google Scholar 

  33. Vischer UM, Emeis JJ, Bilo HJ, Stehouwer CD, Thomsen C, Rasmussen O, et al. von Willebrand factor as a plasma marker of endothelial activation in diabetes: improved reliability with parallel determination of the vWFpropeptide( vWF: AgII). Thromb Haemost 1998; 80: 1002–1007.

    Article  CAS  Google Scholar 

  34. Muntean WE, Borkenstein MH, Haas J. Elevation of factor vIII coagulant activity over factor vIII coagulant antigen in diabetic children without vascular disease. A sign of activation of the factor vIII coagulant moiety during poor diabetes control. Diabetes 1985; 34: 140–144.

    CAS  PubMed  Google Scholar 

  35. Nakano H, Yamado K, Nishimura M, et al. Effect of hypercholesteremia on vascular endothemaylial function and albumin excretion rate in patients with diabetes mellitus. J Nephrol 1996; 38: 507–512.

    CAS  Google Scholar 

  36. Calles-Escandon J, Ballor D, Harvey-Berino J, Ades P, Tracy R, Sobel B. Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction. Am J Clin Nutr 1996; 64: 7–11.

    Article  CAS  Google Scholar 

  37. Anavekar NS, Pfeffer MA. Cardiovascular risk in chronic kidney disease. Kidney Int Suppl 2004; 1992: S11–S15.

    Article  Google Scholar 

  38. De Cosmos S, Minenna A, Ludovico O, Mastroianno S, Di Giorgio A, Pirro L, Trischitta V. Increased urinary albumin excretion, insulin resistance and related cardiovascular risk factors in patients with type 2 diabetes: evidence of a sex specific association. Diabetes Care 2005; 28: 910–915.

    Article  Google Scholar 

  39. Suliman ME, Yilmaz MI, Carrero JJ, Qureshi AR, Saglam M, Ipcioglu OM, et al. Novel links between the long pentraxin 3, endothelial dysfunction and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 976–985.

    Article  CAS  Google Scholar 

  40. Yilmaz MI, Axelsson J, Sonmez A, Carrero JJ, Saglam M, Eyileten T, et al. Effect of rennin angiotensin blockade on pentraxin 3 levels in type 2 diabetic patients with proteinuria. Clin J Am Soc Nephrol 2009; 4: 535–541.

    Article  CAS  Google Scholar 

  41. Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, Bouter Lm. Microalbuminuria is associated with impaired brachial artery, flow mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction: the Hoorn study. Kidney Int Suppl 2004; 1992: S42–S44.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Internal Medicine and Faculty of Medicine, Cairo University, 11461, Cairo, Egypt

    Amr A. El Meligi, Alaa M. Abdel Hamid, Manal A. Aziz, Hemmat E. El Haddadd MD & Elham M. Yousief

  2. Departments of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt

    Marian F. Ishak

Authors
  1. Amr A. El Meligi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alaa M. Abdel Hamid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manal A. Aziz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hemmat E. El Haddadd MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marian F. Ishak
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elham M. Yousief
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hemmat E. El Haddadd MD.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El Meligi, A.A., Hamid, A.M.A., Aziz, M.A. et al. Plasma long pentraxin 3 as a marker of endothelial dysfunction in early diabetic nephropathy. Egypt J Intern Med 25, 117–126 (2013). https://doi.org/10.7123/01.EJIM.0000433328.59695.f9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.7123/01.EJIM.0000433328.59695.f9

Keywords